FDA Oncology Announcements

KRAS inhibitor × Gastrointestinal × Clear all

2 Announcements

FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Trial: CodeBreak300
Drugs: Lumakras (sotorasib) · KRAS inhibitor, Vectibix (panitumumab) · Anti-EGFR antibody
Condition: Gastrointestinal

FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer

Drugs: Krazati (adagrasib) · KRAS inhibitor, cetuximab · Anti-EGFR antibody
Condition: Gastrointestinal